BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37144386)

  • 21. Avoiding New Biopsies by Identification of IDH1 and TERT Promoter Mutation in Nondiagnostic Biopsies From Glioma Patients.
    Barritault M; Picart T; Poncet D; Fenouil T; d'Hombres A; Gabut M; Guyotat J; Jouanneau E; Ameli R; Joubert B; Streichenberger N; Vasiljevic A; Honnorat J; Meyronet D; Ducray F
    Neurosurgery; 2020 Sep; 87(4):E513-E519. PubMed ID: 32107549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of the NRF2 pathway and its impact on the prognosis of anaplastic glioma patients.
    Kanamori M; Higa T; Sonoda Y; Murakami S; Dodo M; Kitamura H; Taguchi K; Shibata T; Watanabe M; Suzuki H; Shibahara I; Saito R; Yamashita Y; Kumabe T; Yamamoto M; Motohashi H; Tominaga T
    Neuro Oncol; 2015 Apr; 17(4):555-65. PubMed ID: 25304134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
    Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
    Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microvascular proliferation of brain metastases mimics glioblastomas in squash cytology.
    Gi T; Sato Y; Tokumitsu T; Yamashita A; Moriguchi-Goto S; Takeshima H; Sato S; Asada Y
    Cytopathology; 2017 Jun; 28(3):228-234. PubMed ID: 27995658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
    Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation.
    Mascelli S; Raso A; Biassoni R; Severino M; Sak K; Joost K; Milanaccio C; Barra S; Grillo-Ruggieri F; Vanni I; Consales A; Cama A; Capra V; Nozza P; Garrè ML
    J Neurooncol; 2012 Sep; 109(3):477-84. PubMed ID: 22821382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status.
    Baldock AL; Yagle K; Born DE; Ahn S; Trister AD; Neal M; Johnston SK; Bridge CA; Basanta D; Scott J; Malone H; Sonabend AM; Canoll P; Mrugala MM; Rockhill JK; Rockne RC; Swanson KR
    Neuro Oncol; 2014 Jun; 16(6):779-86. PubMed ID: 24832620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
    Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G
    Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival.
    Yao Y; Chan AK; Qin ZY; Chen LC; Zhang X; Pang JC; Li HM; Wang Y; Mao Y; Ng HK; Zhou LF
    PLoS One; 2013; 8(6):e67421. PubMed ID: 23840696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
    Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
    Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-Derived Pericytes Driven by EGFR Mutations Govern the Vascular and Immune Microenvironment of Gliomas.
    Segura-Collar B; Garranzo-Asensio M; Herranz B; Hernández-SanMiguel E; Cejalvo T; Casas BS; Matheu A; Pérez-Núñez Á; Sepúlveda-Sánchez JM; Hernández-Laín A; Palma V; Gargini R; Sánchez-Gómez P
    Cancer Res; 2021 Apr; 81(8):2142-2156. PubMed ID: 33593822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas.
    Ohba S; Yamada Y; Murayama K; Sandika E; Sasaki H; Yamada S; Abe M; Hasegawa M; Hirose Y
    World Neurosurg; 2019 Jun; 126():e1042-e1049. PubMed ID: 30878754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
    Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M
    Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
    Wang Y; Zhang T; Li S; Fan X; Ma J; Wang L; Jiang T
    Eur J Neurol; 2015 Feb; 22(2):348-54. PubMed ID: 25318355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas.
    van Opijnen MP; Tesileanu CMS; Dirven L; van der Meer PB; Wijnenga MMJ; Vincent AJPE; Broekman MLD; Dubbink HJ; Kros JM; van Duinen SG; Smits M; French PJ; van den Bent MJ; Taphoorn MJB; Koekkoek JAF
    Neuro Oncol; 2023 Apr; 25(4):701-709. PubMed ID: 35972438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel 3D magnetic resonance fingerprinting radiomics in adult brain tumors: a feasibility study.
    Tippareddy C; Onyewadume L; Sloan AE; Wang GM; Patil NT; Hu S; Barnholtz-Sloan JS; Boyacıoğlu R; Gulani V; Sunshine J; Griswold M; Ma D; Badve C
    Eur Radiol; 2023 Feb; 33(2):836-844. PubMed ID: 35999374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T2 mapping of the peritumoral infiltration zone of glioblastoma and anaplastic astrocytoma.
    Auer TA; Kern M; Fehrenbach U; Tanyldizi Y; Misch M; Wiener E
    Neuroradiol J; 2021 Oct; 34(5):392-400. PubMed ID: 33573473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
    Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
    Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Relationship between IDH1 mutation and clinic pathologic features in human supratentorial WHO grade II gliomas].
    Tang JJ; Xie F; Wang X; Zhang DD; Liu S; Liu YH; Mao Q
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Jan; 44(1):60-3. PubMed ID: 23600211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.